$CRL

Charles River Laboratories (CRL) reported first-quarter results showing modest revenue growth but a net loss and increased impairments, alongside a raised full-year GAAP EPS guidance. The company is actively reshaping its business through significant investments in AI-enabled digital pathology and cell therapy testing collaborations, aiming for improved efficiency and margin recovery. While these strategic shifts indicate a focus on higher-value services, investors are encouraged to consider the impact of rising cancellations and a book-to-bill ratio below 1x on the benefits of these initiatives.